I know it is a well known fact on this forum that ESR and CRP are unreliable while on Actemra. But most rheumatologists don't seem to know that. So I found this one study of many out there that conclude this fact so I can show my rheumatologist and anyone here interested....thank you PMRpro and DL as well as others for pointing this out many times...I had not seen the study for myself until now...
"Tocilizumab is a humanized IgG1 monoclonal antibody that competitively inhibits interleukin 6 (IL‐6) by binding to both its soluble and membrane‐bound receptors, thus blocking the transduction signal triggered by the IL‐6/IL‐6 receptor complex.1 It is approved for the treatment of adult rheumatoid arthritis (RA) patients who have failed to respond to conventional synthetic disease‐modifying antirheumatic drugs (csDMARDs) and/or tumour necrosis factor antagonists.2 It is also approved for systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and giant cell arteritis. Due to the blockade of IL‐6 signalling, tocilizumab inhibits the hepatic production of C‐reactive protein (CRP) and other acute phase proteins like the erythrocyte sedimentation rate (ESR). Thus, CRP and ESR levels rapidly decrease after the initiation of tocilizumab treatment, even before any improvement in swollen or tender joint counts is observed.3 This discrepancy has led to concern on disease activity evaluation in tocilizumab‐treated RA patients."